相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Population pharmacokinetics of tazobactam/ceftolozane in Japanese patients with complicated urinary tract infection and complicated intra-abdominal infection
Makoto Kakara et al.
JOURNAL OF INFECTION AND CHEMOTHERAPY (2019)
Pharmacokinetics and Pharmacodynamics of β-Lactamase Inhibitors
Ryan L. Crass et al.
PHARMACOTHERAPY (2019)
Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance A Randomized Clinical Trial
Patrick N. A. Harris et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia
Alan J. Xiao et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis A Meta-analysis of Individual Patient Data from Randomized Trials
Jason A. Roberts et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2016)
Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model
Anthony M. Nicasio et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
β-lactam and β-lactamase inhibitor combinations in the treatment of extended-spectrum β-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options?
Patrick N. A. Harris et al.
LANCET INFECTIOUS DISEASES (2015)
Protein Binding of β-Lactam Antibiotics in Critically Ill Patients: Can We Successfully Predict Unbound Concentrations?
Gloria Wong et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Pharmacokinetics and Safety of Intravenous Ceftolozane-Tazobactam in Healthy Adult Subjects following Single and Multiple Ascending Doses
Benjamin Miller et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Introduction to Drug Pharmacokinetics in the Critically Ill Patient
Brian S. Smith et al.
CHEST (2012)
Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections:: Prolonged or continuous infusion?
Aryun Kim et al.
PHARMACOTHERAPY (2007)
Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection
CH Li et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2005)
Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion
C Buck et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2005)
Ways to fit a PK model with some data below the quantification limit
SL Beal
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2001)
Pharmacokinetic and pharmacodynamic profile of high dose extended interval piperacillin-tazobactam
MK Kim et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2001)
分享论文
